Ortho Clinical Diagnostics has launched its Kapa Free Light Chain and Lambda Free Light Chain assays in collaboration with Diazyme Laboratories. The assays are being made available through its MicroTip Partnership Assay program, which was established to validate third-party assays for use on Ortho Clinical's platforms. The company also said that it will offer the methotrexate assay in collaboration with Ark Diagnostics and Sekisui Diagnostics.
The Kappa Free Light Chain and Lambda Free Light Chain assays are recommended for diagnosing and monitoring plasma cell disorders such as multiple myeloma, lymphoid neoplasms, and amyloidosis. The metrotrexate assay is for monitoring methotrexate, a drug prescribed to patients with certain neoplastic diseases, including osteogenic sarcoma, leukemia, non-Hodgkin's lymphoma, and breast and lung cancer, and others.
The three assays have been validated for use with Ortho Clinical's Vitros 5600 Integrated System and Vitros 4600 Chemistry System. The Kappa Free Light Chain and Lambda Free Light Chain assays will be available in the US, Europe, Middle East, and Africa. The methotrexate assay will be available in the US.